The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
    Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.